Pfizer is ending development of its once-daily obesity pill danuglipron after a trial participant suffered possible liver injury. The decision halts early-stage testing and cancels plans for ...

Explore how Trump's tariffs affect corporate strategies and consumer prices in America amid changing import dynamics.

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Pfizer (PFE) with a Neutral rating and $24 price target Pfizer made “concrete progress” on its cost-base and margins over 2024 ...

Pfizer (PFE) announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

Pfizer plans to explore other obesity treatments for testing. Pfizer is halting the development of its potential pill for treating obesity following an injury that happened during a clinical trial.

Pharmaceutical giant Pfizer sold its longtime San Diego campus to a life science-focused commercial real estate company in one of the largest deals of the past year. Pfizer sold the five ...

Pfizer (NYSE:PFE) is scheduled to report earnings on Tuesday, April 29, 2025. Looking at PFE’s five-year history, the stock has shown an exact 50-50 split between positive and negative returns ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in ...